RT Journal Article
SR Electronic
T1 Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 697
OP 700
DO 10.3899/jrheum.170150
VO 44
IS 5
A1 Ogdie, Alexis
A1 de Wit, Maarten
A1 Callis Duffin, Kristina
A1 Campbell, Willemina
A1 Chau, Jeffrey
A1 Coates, Laura C.
A1 Eder, Lihi
A1 Elmamoun, Musaab
A1 FitzGerald, Oliver
A1 Gladman, Dafna D.
A1 Goel, Niti
A1 James, Jana
A1 Kalyoncu, Umut
A1 Latella, John
A1 Lindsay, Chris
A1 Mease, Philip J.
A1 O’Sullivan, Denis
A1 Steinkoenig, Ingrid
A1 Strand, Vibeke
A1 Tillett, William
A1 Orbai, Ana-Maria
YR 2017
UL http://www.jrheum.org/content/44/5/697.abstract
AB The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group recently published the updated 2016 psoriatic arthritis (PsA) core domain set, a set of disease features that should be measured in all clinical trials. At the GRAPPA annual meeting in July 2016, the PsA working group presented the updated PsA core domain set endorsed by 90% of participants at OMERACT in May 2016 and drafted a roadmap for the development of the PsA core outcome measurement set. In this manuscript, we review the development process of the PsA core domain set and the ongoing and proposed work streams for development of a PsA core measurement set.